COVID-19 vaccine boosters could mean billions for drugmakers

COVID-19 vaccine boosters could mean billions for drugmakers
In this March 2021 photo provided by Pfizer, a technician works on a line for packaging preparation for the Pfizer-BioNTech COVID-19 vaccine at the company’s facility in Puurs, Belgium. Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus. Credit: Pfizer via AP

Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus.

How much the manufacturers stand to gain depends on how big the rollout proves to be.

U.S. health officials late on Thursday endorsed booster shots of the Pfizer for all Americans 65 and older—along with tens of millions of younger people who are at higher risk from the coronavirus because of health conditions or their jobs.

Officials described the move as a first step. Boosters will likely be offered even more broadly in the coming weeks or months, including boosters of vaccines made by Moderna and Johnson & Johnson. That, plus continued growth in initial vaccinations, could mean a huge gain in sales and profits for Pfizer and Moderna in particular.

“The opportunity quite frankly is reflective of the billions of people around the world who would need a vaccination and a boost,” Jefferies analyst Michael Yee said.

Wall Street is taking notice. The average forecast among analysts for Moderna’s 2022 revenue has jumped 35% since President Joe Biden laid out his plan in mid-August.

Most of the vaccinations so far in the U.S. have come from Pfizer, which developed its shot with Germany’s BioNTech, and Moderna. They have inoculated about 99 million and 68 million people, respectively. Johnson & Johnson is third with about 14 million people.

No one knows yet how many people will get the extra shots. But Morningstar analyst Karen Andersen expects boosters alone to bring in about $26 billion in next year for Pfizer and BioNTech and around $14 billion for Moderna if they are endorsed for nearly all Americans.

COVID-19 vaccine boosters could mean billions for drugmakers
This Sept. 21, 2021 file photo shows vials of the Pfizer and Moderna COVID-19 vaccines in Jackson, Miss. Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus. Credit: AP Photo/Rogelio V. Solis

Those companies also may gain business from people who got other vaccines initially. In Britain, which plans to offer boosters to everyone over 50 and other vulnerable people, an expert panel has recommended that Pfizer’s shot be the primary choice, with Moderna as the alternative.

Andersen expects Moderna, which has no other products on the market, to generate a roughly $13 billion profit next year from all COVID-19 vaccine sales if boosters are broadly authorized.

Potential vaccine profits are harder to estimate for Pfizer, but company executives have said they expect their pre-tax adjusted profit margin from the vaccine to be in the “high 20s” as a percentage of revenue. That would translate to a profit of around $7 billion next year just from boosters, based on Andersen’s sales prediction.

J&J and Europe’s AstraZeneca have said they don’t intend to profit from their COVID-19 vaccines during the pandemic.

For Pfizer and Moderna, the boosters could be more profitable than the original doses because they won’t come with the research and development costs the companies incurred to get the vaccines on the market in the first place.

WBB Securities CEO Steve Brozak said the booster shots will represent “almost pure profit” compared with the initial doses.

Drugmakers aren’t the only businesses that could see a windfall from delivering boosters. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue, according to Jeff Jonas, a with Gabelli Funds.

Jonas noted that the drugstores may not face competition from mass vaccination clinics this time around, and the chains are diligent about collecting customer contact information. That makes it easy to invite people back for boosters.

COVID-19 vaccine boosters could mean billions for drugmakers
In this May 3, 2021 file photo, a man holds his vaccination reminder card after having received his first shot at a pop-up vaccination site in the Little Havana neighborhood of Miami. Billions more in profits are at stake for some vaccine makers as the U.S. moves toward dispensing COVID-19 booster shots to shore up Americans’ protection against the virus. Drugstore chains CVS Health and Walgreens could bring in more than $800 million each in revenue, according to Jeff Jonas, a portfolio manager with Gabelli Funds. Credit: AP Photo/Wilfredo Lee

Drugmakers are also developing COVID-19 shots that target certain variants of the virus, and say people might need annual shots like the ones they receive for the flu. All of that could make the vaccines a major recurring source of revenue.

The COVID-19 vaccines have already done much better than their predecessors.

Pfizer said in July it expects revenue from its COVID-19 vaccine to reach $33.5 billion this year, an estimate that could change depending on the impact of boosters or the possible expansion of shots to .

That would be more than five times the $5.8 billion racked up last year by the world’s most lucrative vaccine—Pfizer’s Prevnar13, which protects against pneumococcal disease.

It also would dwarf the $19.8 billion brought in last year by AbbVie’s rheumatoid arthritis treatment Humira, widely regarded as the world’s top-selling drug.

This bodes well for future vaccine development, noted Erik Gordon, a business professor at the University of Michigan.

Vaccines normally are nowhere near as profitable as treatments, Gordon said. But the success of the COVID-19 shots could draw more drugmakers and venture capitalists into the field.

“The vaccine business is more attractive, which, for those of us who are going to need vaccines, is good,” Gordon said.



© 2021 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed without permission.

Citation: COVID-19 vaccine boosters could mean billions for drugmakers (2021, September 25) retrieved 2 October 2021 from https://medicalxpress.com/news/2021-09-covid-vaccine-boosters-billions-drugmakers.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Note: This article have been indexed to our site. We do not claim ownership or copyright of any of the content above. To see the article at original source Click Here

Related Posts
COVID Vax in Parents Provides Strong Protection for Children thumbnail

COVID Vax in Parents Provides Strong Protection for Children

Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Parents who keep up to date with their COVID-19 vaccines may help protect their unvaccinated children from the disease in the process, new research shows. Having one fully vaccinated parent reduced the risk for infection with the original strain of SARS-CoV-2…
Read More
Single-Dose Antibiotic Reduced Maternal Sepsis in Vaginal Delivery thumbnail

Single-Dose Antibiotic Reduced Maternal Sepsis in Vaginal Delivery

Meeting Coverage > SMFM — Azithromycin did not lower stillbirth, newborn sepsis, or newborn death risk, however by Ed Susman, Contributing Writer, MedPage Today February 9, 2023 Pregnant women considering vaginal deliveries had a lower risk of developing sepsis during childbirth if they were treated with a single dose of the antibiotic azithromycin, a multinational
Read More
Trump Claimed He’s a ‘Leader on IVF’ During the Debate. His Record Suggests Otherwise thumbnail

Trump Claimed He’s a ‘Leader on IVF’ During the Debate. His Record Suggests Otherwise

While discussing one of the most anticipated topics of the first (and possibly only) 2024 presidential debate, former president Donald Trump boldly claimed to be “a leader on IVF” (in-vitro fertilization) after moderators asked whether Americans should trust him on the issue of abortion—and, more specifically, whether he would veto a nationwide ban on the
Read More
5 most competitive zodiac signs thumbnail

5 most competitive zodiac signs

Each zodiac sign has unique qualities and characteristics and these signs are often associated with being more driven and competitive.Aries is often associated with a competitive spirit. They are known for their assertiveness, drive, and desire to be the best.Aries Leos are seen as competitive, particularly in situations where they can be in the spotlight and
Read More
Index Of News
Total
0
Share